Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptika, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

viiv healthcare b.v. - fostemsavir trometamol - hiv infekce - antivirotika pro systémové použití - rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant hiv-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - pohlavní hormony a modulátory genitálního systému, - orální antikoncepce. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.

Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastická činidla - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 4951 kyselina valproovÁ - enterosolventní měkká tobolka - 150mg - kyselina valproovÁ

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 4951 kyselina valproovÁ - enterosolventní měkká tobolka - 300mg - kyselina valproovÁ

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 1939 natrium-valproÁt - perorální roztok - 300mg/ml - kyselina valproovÁ

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 1939 natrium-valproÁt - sirup - 50mg/ml - kyselina valproovÁ

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 4951 kyselina valproovÁ - enterosolventní měkká tobolka - 500mg - kyselina valproovÁ

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

sanofi s.r.o., praha array - 1939 natrium-valproÁt - prášek a rozpouštědlo pro injekční roztok - 400mg/4ml - kyselina valproovÁ